April 19, 2017
11 am to 12 pm EDT

Sponsored by

Webinar Description:

Reliable and robust bioanalytical methods are the cornerstone for generating pharmacokinetic (PK), biomarker and immunogenicity (ADA) data for biotherapeutic development and subsequent regulatory submission. Ligand binding assays (LBAs) used for quantification of biotherapeutic drugs rely on specific critical reagents that are often in limited supply. Traditional manual methods for LBA reagent selection and characterization are labor intensive and are subject to long cycle times, volume limitations and matrix effects. Gyrolab immunoassay platforms automate assay workflows and provide higher throughput, using only microliter volumes with results in under an hour. Thus, Gyrolab streamlines reagent selection and characterization of biotherapeutics for more robust assay performance which improves productivity and reduces project timelines.

Learning Objectives:

• Gyrolab is a reliable immunoassay platform that streamlines reagent selection and characterization during method development for biotherapeutics
• Rapid screening and selection of anti-Idiotypic antibodies (anti-IDs) using microliter volumes of cell supernatants for binding affinity, specificity, drug target interference used in LBA assay development
• Due to limited sample volume, a novel, semi-automated, multiplexed custom Gyrolab method was developed to identify up to eight different antibody isotypes in clinical samples using (5 uL) of sample

Speakers:

Frank Zambito, Research Scientist I

Bioanalytical Sciences

Bristol-Myers Squibb

Shawn Fernando

Senior Principal Researcher

Morphotek, Inc.

Moderator:

Robert Durham, Ph.D.

Director of Field Applications

Gyros Protein Technologies